As of Apr 26
| -6.91 / -2.41%|
The 26 analysts offering 12-month price forecasts for Biogen have a median target of 312.50, with a high estimate of 380.00 and a low estimate of 260.00. The median estimate represents a +11.62% increase from the last price of 279.98.
The current consensus among 30 polled investment analysts is to Buy stock in Biogen. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.